Inhibikase Therapeutics
IKT
IKT
74 hedge funds and large institutions have $218M invested in Inhibikase Therapeutics in 2025 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 27 increasing their positions, 15 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
67.79% more ownership
Funds ownership: 73.76% → 141.56% (+68%)
37% more funds holding
Funds holding: 54 → 74 (+20)
Holders
74
Holding in Top 10
5
Calls
–
Puts
–
Top Buyers
| 1 | +$9.31M | |
| 2 | +$7.24M | |
| 3 | +$6.14M | |
| 4 |
Blackstone Inc
New York
|
+$5.25M |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$4.48M |
Top Sellers
| 1 | -$82.1K | |
| 2 | -$77K | |
| 3 | -$66.4K | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$40.7K |
| 5 |
JP Morgan Chase
New York
|
-$39.9K |
